2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.04 Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer

EP.12A.04 Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study from the Ohio State University – James Comprehensive Cancer Center evaluates the patterns and impacts of dose reduction of osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib has generally shown superior overall survival advantages and effective central nervous system (CNS) activity compared to earlier generation TKIs, especially in treatment-naive EGFR-positive NSCLC patients. This is significant since approximately 40% of NSCLC patients with EGFR mutations have brain metastases at diagnosis.<br /><br />The study analyzed 94 patients treated with first-line osimertinib between 2017 and 2023 through retrospective chart reviews. The primary focus was to explore the relationship between dose reductions of osimertinib and different outcomes like survival and CNS disease progression.<br /><br />Key findings revealed that dose reduction occurred in 21% of patients, often among older individuals, but was not associated with decreased survival or increased CNS progression. The median overall survival was 26.7 months, slightly shorter than in broader published trials, likely due to the higher risk profile of patients in this cohort. Importantly, patients' age was correlated with dose reduction, but factors like sex were not. These results suggest that dose reductions do not adversely affect survival or cause differences in CNS progression.<br /><br />The study, with its single-center and relatively small sample size, highlighted the need for future research examining combined therapy strategies, patient quality of life, and outcomes with osimertinib in various therapeutic settings. Understanding these elements could further optimize treatment regimens for patients with EGFR-positive NSCLC.

Asset Subtitle

Dwight Owen

Meta Tag

Speaker Dwight Owen

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

osimertinib

EGFR mutation

non-small cell lung cancer

dose reduction

survival outcomes

CNS activity

brain metastases

retrospective study

treatment-naive patients

therapy optimization